探索局部晚期非小细胞肺癌放化疗后度伐利尤单抗早期停药的原因与后果
本研究回顾性分析了2017至2021年间接受根治性放化疗后开始辅助度伐利尤单抗治疗的59例局部晚期非小细胞肺癌患者,69%患者早期停药,最常见原因为疾病进展(14例)和肺毒性(10例)。多变量分析显示心脏平均放疗剂量与因疾病进展停药风险相关(HR=2.34/10 Gy,p=0.052),早期停药与更差结局相关,心脏受照剂量可能是免疫治疗停药、疾病复发和死亡的风险因素。
要点
- 59例中41例(69%)早期停用度伐利尤单抗,最常见原因为疾病进展(14例)和肺毒性(10例)。
- 心脏平均放疗剂量与因进展停药风险相关(HR=2.34/10 Gy,p=0.052)。
- 完成1年度伐利尤单抗者2年PFS为100% vs 40%(p<0.001),2年OS为100% vs 67%(p=0.862)。
核心结论
- 对于接受放化疗后免疫治疗的局部晚期非小细胞肺癌患者,心脏受照范围可能是免疫治疗停药、疾病复发和死亡的风险因素。
研究设计与样本
- 回顾性分析2017至2021年间接受根治性放化疗并开始辅助度伐利尤单抗治疗的局部晚期非小细胞肺癌患者59例。
- 采用逻辑回归模型评估早期停用度伐利尤单抗的预测因素。
- 采用界标分析(landmark analyses)探索早期停药与临床结局(无进展生存期PFS、总生存期OS)之间的关联。
主要发现
- 59例患者中41例(69%)早期停用度伐利尤单抗,最常见原因为疾病进展(n=14)和肺毒性(n=10)。
- 多变量分析显示心脏平均放疗剂量与因疾病进展停用度伐利尤单抗的风险相关(HR=2.34/10 Gy,p=0.052)。
- 心脏平均放疗剂量与因肺毒性停用度伐利尤单抗风险之间的关联呈趋势(HR=2.16/10 Gy,p=0.126)。
- 开始度伐利尤单抗后中位PFS为14个月,中位OS为32个月。
- 界标分析排除开始度伐利尤单抗后1年内进展或死亡的患者后,完成1年度伐利尤单抗者2年PFS为100% vs 40%(p<0.001),2年OS为100% vs 67%(p=0.862)。
关键数值与推荐
- 对于完成根治性放化疗且未出现疾病进展的局部晚期非小细胞肺癌患者,推荐辅助度伐利尤单抗治疗1年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: For most locally advanced non-small cell lung cancer (LA-NSCLC) patients who complete definitive chemoradiotherapy (CRT) and do not experience disease progression, one year of adjuvant durvalumab is recommended. Here, we explore causes and consequences of early durvalumab discontinuation. MATERIALS AND METHODS: We reviewed patients treated for LA-NSCLC with definitive CRT who began adjuvant durvalumab between 2017 and 2021. Duration of durvalumab receipt and causes for early discontinuation were tabulated. Logistic regression models were utilized to evaluate predictors of early durvalumab discontinuation. Landmark analyses were performed to explore associations between early durvalumab discontinuation and clinical outcomes (progression-free survival (PFS), overall survival (OS)). RESULTS: Fifty-nine patients were included. Forty-one patients (69%) discontinued durvalumab early, most commonly for disease progression (n = 14) or lung toxicity (n = 10). Multivariable analysis revealed mean heart radiotherapy dose (MHD) was associated with risk of durvalumab discontinuation from progression (HR = 2.34 per 10 Gy, p = 0.052), and there was a trend suggesting an association between MHD and risk of durvalumab discontinuation from lung toxicity (HR = 2.16 per 10 Gy, p = 0.126). Median PFS duration following durvalumab initiation was 14 months, and median OS duration was 32 months. Landmark analyses that excluded patients with progression or death within one year of durvalumab initiation demonstrated improved outcomes for patients who completed one year of durvalumab (2-year PFS 100% v. 40%, p < 0.001; 2-year OS 100% v. 67%, p = 0.862). Improved outcomes were observed for patients who received MHD below the cohort median (9.3 Gy) compared to patients with higher MHD (median PFS 32 months v. 8 months, p < 0.001; 2-year OS 69% v. 44%, p = 0.088). CONCLUSION: For LA-NSCLC patients treated with CRT followed by immunotherapy, extent of cardiac irradiation may be a risk factor for immunotherapy discontinuation, disease recurrence, and death.
引用
- Pennock M, Halmos B, Bodner W, et al. Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer. Clin Transl Radiat Oncol. 2023. PMID: 37346274. doi:10.1016/j.ctro.2023.100643
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。